issuer: Intercell AG Campus Vienna Biocenter 3 A-1030 Wien phone: +43 1 20620-0 FAX: +43 1 20620-800 mail: investors@intercell.com WWW: www.intercell.com sector: Biotechnology ISIN: AT0000612601 indexes: ATX Prime, ATX stockmarkets: official market: Wien language: English Contact: Intercell AG Nina Waibel ...
company: Intercell AG Campus Vienna Biocenter 3 A-1030 Wien phone: +43 1 20620-0 FAX: +43 1 20620-800 mail: investors@intercell.com WWW: www.intercell.com sector: Biotechnology ISIN: AT0000612601 indexes: ATX Prime, ATX stockmarkets: official market: Wien language: English Contact: Intercell AG Nina Waibel ...
Contact: Intercell AG Nina Waibel Corporate Communications Tel. +43 1 20620-1222 communications@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Index: ATX Prime, ATX Börsen: Wien / official market ...
Contact: Intercell AG Nina Waibel Corporate Communications Tel. +43 1 20620-1222 communications@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Index: ATX Prime, ATX Börsen: Wien / official market ...
Contact: Intercell AG Nina Waibel Corporate Communications Tel. +43 1 20620-1222 communications@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Index: ATX Prime, ATX Börsen: Wien / official market ...
Contact: Intercell AG Nina Waibel Corporate Communications Tel. +43 1 20620-1222 communications@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Index: ATX Prime, ATX Börsen: Wien / official market ...
Contact: Intercell AG Nina Waibel Corporate Communications Tel. +43 1 20620-1222 communications@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Index: ATX Prime, ATX Börsen: Wien / official market ...
Contact: Intercell AG Lucia Malfent Vice President, Global Head Corporate Communications Tel. +43 1 20620-1303 lmalfent@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Index: ATX Prime, ATX Börsen: Wien / official market ...
Contact: Intercell AG Lucia Malfent Vice President, Global Head Corporate Communications Tel. +43 1 20620-1303 lmalfent@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Index: ATX Prime, ATX Börsen: Wien / official market ...
Contact: Intercell AG Lucia Malfent Vice President, Global Head Corporate Communications Tel. +43 1 20620-1303 lmalfent@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Index: ATX Prime, ATX Börsen: Wien / official market ...
- » First pivotal Phase II/III trial in endemic region towards licensure of a novel pediatric vaccine to prevent Japanese Encephalitis (JE), manufactured by Intercell's partner, Biological E. » Important development step towards a modern, cell culture-derived product in endemic countries first country approval ...
- » After successful pre-clinical trials, Intercell is progressing its vaccine candidate against Clostridium difficile, the major cause of nosocomial diarrhea, into the clinical development stage » Initiation of a first-in-man Phase I clinical trial in healthy subjects » Study aims to obtain safety and ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Rep. purs. Sec. 159 para 3 and para 2 and section 95 para 6 Vienna, December 15, 2010 - (euro adhoc) - Stock Option Program Pursuant to Section 4.11 of the Articles ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Publ. purs. to Sec 4 and 5 of Publication Ordinance 2002 Vienna, December 15, 2010 - (euro adhoc) - Since 2002, the shareholders meeting of INTERCELL AG has issued ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 12.12.2010 » Travelers' Diarrhea vaccine candidate failed to meet efficacy endpoints to protect against enterotoxigenic ...
- » Primary Immunogenicity and Safety objectives met » All formulations of V710 were immunogenic following a single or two-dose application Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Research & Development Subtitle: - » ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 9-month report 09.11.2010 Positive sales trend of IXIARO®/JESPECT® vaccine against Japanese Encephalitis - Focused R&D spending on late-stage programs and negative currency effects lead to EUR ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 25.10.2010 » Primary Immunogenicity and Safety Endpoints met » Significant reduction of mortality observed versus alum ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 21.10.2010 » The companies are designing a treatment that combines Intercell's investigational Hepatitis C vaccine, IC41, with Romark's antiviral drug, nitazoxanide. » A ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 30.09.2010 Vienna (Austria), September 30, 2010 - Intercell AG (VSE: ICLL) today announced that effective October 1, 2010, Staph Leavenworth Bakali ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 6-month report 17.08.2010 Significant increase in product sales totaling EUR 5.2m in Q2 2010 - strongest quarter since IXIARO®/JESPECT® launch R&D pipeline progress according to plan ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 20.07.2010 Since 2002, the shareholders meeting of Intercell AG has issued stock options on a regular basis to members of the management board, the ...
Intercell's vaccine to help prevent Japanese Encephalitis now available in Switzerland Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information Subtitle: Intercell's vaccine to help prevent Japanese Encephalitis now available in Switzerland Vienna (Austria), July 13, 2010 (euro adhoc) - Intercell AG (VSE: ICLL) announces ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 02.07.2010 Vienna (Austria)/Gaithersburg (USA), July 2, 2010 - Intercell AG (VSE: ICLL) today announced the results of a ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Strategic management decisions Vienna (Austria), June 8, 2010 (euro adhoc) - Intercell AG (VSE: ICLL) today announced the closing of the acquisition of Cytos' platform technology for monoclonal antibody discovery. On May 6, ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Annual & Special Corporate Meetings Vienna (Austria), June 4, 2010 (euro adhoc) - - I. The ordinary shareholders´ meeting of Intercell AG for the business year 2010 will take place on Friday, June 25, 2010, at 2.00 p.m. at the ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information Vienna (Austria)/Washington (USA), May 25, 2010 (euro adhoc) - Intercell AG (VSE: ICLL) has been honored in a ceremony at the Pentagon today for the company´s ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 3-month report 11.05.2010 Good progress in vaccine development programs - Strong R&D spending in late-stage programs lead to EUR 14.7 m loss in the first quarter Vienna (Austria), May 11, 2010 - ...
- » Worldwide agreement for the use of certain Intercell's AIP®-derived antigens to develop and commercialize animal vaccines » Intercell to receive upfront, option and milestone payments as well as royalties on product net sales Corporate news transmitted by euro adhoc. The issuer/originator is ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 06.05.2010 Vienna (Austria), May 6, 2010 - Intercell AG (VSE: ICLL) today announced that it has signed an agreement with ...